ERT Awarded Preferred Provider Status

News

ERT Awarded Preferred Provider Status

28 Feb, 2014

Published over 12 years ago. See the latest and most current information on News.

 ERT, a leading global solution provider for patient safety and efficacy endpoint data collection, has been named a preferred provider for the administration of the EuroQol Group’s EQ-5D patient reported outcome (PRO) assessment.  Specifically, VIAPhone, ERT’s Interactive Voice Response (IVR) system, has been approved to capture both the EQ-5D-3L and the EQ-5D-5L versions of the quality of life assessment. 

The EuroQol Group – the copyright owner of the scale – conferred  preferred provider status to ERT based on its established process for ensuring compliant and high-quality electronic implementations of this scale.

“We are pleased that ERT can now offer its customers a reliable option for capturing important health outcomes information via IVR administration of the EQ-5D,” said Gerben Bakker, User Support Officer, EuroQol Group. “This offering will enable biopharmaceutical researchers to evaluate whether patients’ health states are impacted by new medical treatments.”

 “Being named a preferred provider verifies that the scientific foundation upon which our electronic COA solutions are built meets the high standards set by EuroQol,” said Bob Young, Executive Vice President, COA Solutions, ERT. “We are pleased to receive this recognition and look forward to continuing our long-term relationship with the EuroQol Group."

Latest News

Lab Asia 33.4 - August 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
FM approval strengthens intelligent fixed gas detection for refineries and petrochemical plants
Explore more Arrow
Pollution Solutions Online
Slurry grant a fossil fuel failure?
Explore more Arrow
Petro Online
Precision by weight: The critical role of gravimetric blending in fuel certification
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow